

Gerald J Dal Pan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9514839/publications.pdf>

Version: 2024-02-01

18
papers

387
citations

840585

11
h-index

839398

18
g-index

18
all docs

18
docs citations

18
times ranked

352
citing authors

#	ARTICLE	IF	CITATIONS
1	The Use of Real-World Data to Assess the Impact of Safety-Related Regulatory Interventions. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 98-107.	2.3	3
2	“Artificial Intelligence” for Pharmacovigilance: Ready for Prime Time?. <i>Drug Safety</i> , 2022, 45, 429-438.	1.4	21
3	Trend changes of national zolpidem users and exposure cases after FDA drug safety communications. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1551-1559.	0.9	1
4	Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility. <i>Drug Safety</i> , 2020, 43, 329-338.	1.4	15
5	Changes in emergency department visits for zolpidem-attributed adverse drug reactions after FDA Drug Safety Communications. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 352-356.	0.9	4
6	An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System. <i>Drug Safety</i> , 2020, 43, 457-465.	1.4	13
7	Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem. <i>Drug Safety</i> , 2019, 42, 1287-1295.	1.4	13
8	Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey. <i>Journal of Law, Medicine and Ethics</i> , 2019, 47, 430-441.	0.4	9
9	The Impact of Litigation-Associated Reports on Signal Identification in the US FDA’s Adverse Event Reporting System. <i>Drug Safety</i> , 2019, 42, 1199-1201.	1.4	3
10	Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance. <i>Drug Safety</i> , 2019, 42, 649-655.	1.4	14
11	Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 390-400.	2.3	31
12	Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis. <i>JMIR Public Health and Surveillance</i> , 2018, 4, e1.	1.2	21
13	Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 712-721.	0.9	27
14	Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications. <i>Drug Safety</i> , 2015, 38, 565-575.	1.4	31
15	Ongoing Challenges in Pharmacovigilance. <i>Drug Safety</i> , 2014, 37, 1-8.	1.4	41
16	Evaluation of FDA safety-related drug label changes in 2010. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 302-305.	0.9	91
17	Communicating the Risks of Medicines. <i>Medical Care</i> , 2012, 50, 463-465.	1.1	16
18	Post-market drug safety evidence sources: an analysis of FDA drug safety communications. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 1134-1136.	0.9	33